Polydex Pharmaceuticals Ltd (POLXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 01/31
(Values in U.S. thousands)
| 04-2023 | 01-2023 | 10-2022 | 07-2022 | 04-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -153 | -766 | -770 | -387 | -77 |
| Depreciation Amortization | 104 | 328 | 249 | 169 | 85 |
| Accounts receivable | N/A | -73 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | -149 | N/A | N/A | N/A |
| Other Working Capital | -120 | -412 | -392 | -290 | -238 |
| Other Operating Activity | 0 | 221 | 0 | 0 | 0 |
| Operating Cash Flow | $-170 | $-850 | $-912 | $-507 | $-231 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -16 | -171 | -105 | -53 | -46 |
| Purchase Of Investment | -3 | 369 | -13 | -9 | -2 |
| Sale Of Investment | 152 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $134 | $198 | $-117 | $-62 | $-49 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -1 | -127 | -12 | -12 | -6 |
| Other Financing Activity | -13 | -57 | -44 | -30 | -15 |
| Financing Cash Flow | $-15 | $-184 | $-56 | $-42 | $-22 |
| Exchange Rate Effect | -2 | 106 | 228 | 44 | 19 |
| Beginning Cash Position | 300 | 1,030 | 1,030 | 1,030 | 1,030 |
| End Cash Position | 247 | 300 | 173 | 462 | 749 |
| Net Cash Flow | $-53 | $-731 | $-858 | $-568 | $-282 |
| Free Cash Flow | |||||
| Operating Cash Flow | -170 | -850 | -912 | -507 | -231 |
| Capital Expenditure | -16 | -171 | -105 | -53 | -46 |
| Free Cash Flow | -185 | -1,021 | -1,017 | -561 | -277 |